Xifaxan Alternatives Compared
| Xifaxan (rifaximin) | Viberzi (eluxadoline) | Lotronex (alosetron) |
|
|---|
| Xifaxan (rifaximin) | Viberzi (eluxadoline) | Lotronex (alosetron) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Hepatic Encephalopathy, Irritable Bowel Syndrome with Diarrhea, Irritable Bowel Syndrome, Traveler's Diarrhea, Diarrhea. Xifaxan may also be used for purposes not listed in this... View more |
Prescription only
Prescribed for Irritable Bowel Syndrome with Diarrhea, Diarrhea, Irritable Bowel Syndrome. Viberzi may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Irritable Bowel Syndrome with Diarrhea, Irritable Bowel Syndrome, Diarrhea. Lotronex may also be used for purposes not listed in this medication guide. |
Related suggestions Irritable Bowel Syndrome
Irritable Bowel Syndrome with Diarrhea
Popular comparisons
|
|||||||||||||||||||||||
| More about Xifaxan (rifaximin) | More about Viberzi (eluxadoline) | More about Lotronex (alosetron) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Xifaxan has an average rating of 6.5 out of 10 from a total of 95 ratings on Drugs.com. 59% of reviewers reported a positive effect, while 35% reported a negative effect. |
Viberzi has an average rating of 6.7 out of 10 from a total of 217 ratings on Drugs.com. 57% of reviewers reported a positive effect, while 25% reported a negative effect. |
Lotronex has an average rating of 9.6 out of 10 from a total of 24 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Xifaxan side effects |
View all Viberzi side effects |
View all Lotronex side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Xifaxan prices |
View all Viberzi prices |
View all Lotronex prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
10.19 hours |
6 hours |
1.5 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Some potential for abuse
Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 89 drugs are known to interact with Xifaxan:
|
A total of 213 drugs are known to interact with Viberzi:
|
A total of 89 drugs are known to interact with Lotronex:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
May 25, 2004 |
May 27, 2015 |
February 09, 2000 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.